Article Abstract

Men on active surveillance without cancer on biopsy are less likely to reclassify

Authors: Jan F. M. Verbeek, Monique J. Roobol, Chris H. Bangma


The manuscript of Kearns et al. based on data from the multicenter Canary Prostate Active Surveillance Study (PASS) reports on surveillance biopsies with benign result as prognostic marker for less reclassification to higher risk disease (1). The PASS cohort included men from 2008 with clinically localized low risk prostate cancer (cT1-2c disease, no previous treatment, and Gleason ≤3+4 disease).